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Abstract
Objective
To analyze whether 1 of the 2 apheresis techniques, therapeutic plasma exchange (PE) or immunoadsorption (IA), is superior
in treating neuromyelitis optica spectrum disorder (NMOSD) attacks and to identify predictive factors for complete
remission (CR).
Methods
This retrospective cohort study was based on the registry of the German Neuromyelitis Optica Study Group, a nationwide network
established in 2008. It recruited patients with neuromyelitis optica diagnosed according to the 2006 Wingerchuk criteria or with
aquaporin-4 (AQP4-ab)-antibody–seropositive NMOSD treated at 6 regional hospitals and 16 tertiary referral centers until March
2013. Besides descriptive data analysis of patient and attack characteristics, generalized estimation equation (GEE) analyses were
applied to compare the effectiveness of the 2 apheresis techniques. A GEE model was generated to assess predictors of outcome.
Results
Two hundred and seven attacks in 105 patients (87% AQP4-ab-antibody seropositive) were treated with at least 1 apheresis
therapy. Neither PE nor IA was proven superior in the therapy of NMOSD attacks. CR was only achieved with early apheresis
therapy. Strong predictors for CR were the use of apheresis therapy as first-line therapy (OR 12.27, 95% CI: 1.04–144.91, p =
0.047), time from onset of attack to start of therapy in days (OR 0.94, 95% CI: 0.89–0.99, p = 0.014), the presence of AQP4-ab-
antibodies (OR 33.34, 95% CI: 1.76–631.17, p = 0.019), and monofocal attack manifestation (OR 4.71, 95% CI: 1.03–21.62, p =
0.046).
Conclusions
Our findings suggest early use of an apheresis therapy in NMOSD attacks, particularly in AQP4-ab-seropositive patients. No
superiority was shown for one of the 2 apheresis techniques.
Classification of evidence
This study provides Class IV evidence that for patients with NMOSD, neither PE nor IA is superior in the treatment of
attacks.
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Adequate treatment of attacks in neuromyelitis optica spec-
trum disorders (NMOSDs) is crucial as long-term disability in
these patients is accumulated by poor recovery from
attacks.1,2 We have previously shown in a retrospective ana-
lysis that aggressive treatment of attacks, particularly escala-
tion of attack therapy, can improve the attack outcome with
the sequence of treatments being crucial.3 In particular, our
study suggested that first-line therapy with apheresis therapies
may be superior to high-dose steroid pulse therapy in attacks
involving the spinal cord.
Apheresis therapies aim to eliminate pathogenic antibodies
and other proinflammatory factors from the patient’s circu-
lation. Two major techniques are used. Therapeutic plasma
exchange (PE) separates patient’s plasma from the whole
blood.4 Centrifugation devices or highly permeable filters are
used to separate the plasma filtrate with molecules up to 1,000
kD, including immunoglobulins, complement factors, and
albumin from blood cells. The plasma filtrate is discarded, and
either 5% albumin solution or fresh-frozen plasma is added to
the filtered blood before reinfusion. For immunoadsorption
(IA), plasma separation is equally needed as the first step.5
The plasma fraction is then passed through an IA device.
Single-pass devices use tryptophan as an adsorber, whereas
reusable devices use in most cases the Staphylococcus aureus
cell wall–derived protein A. Several plasma constituents,
including immunoglobulins and complement, are removed
from the plasma, whereas albumin and clotting factors are
mostly spared and reinfused. Besides the immediate intra-
vasal reduction of autoantibodies, e.g., those targeting
aquaporin-4 (AQP4-ab),6 PE and IA also show effects on
immunoglobulin redistribution and subsequent immuno-
modulatory changes.7–10
It remains to be elucidated whether one of the apheresis
therapies might be superior in the treatment of NMOSD
attacks. We therefore conducted a retrospective analysis of
207 NMOSD attacks in 105 patients who were treated either
with PE or IA and aimed to identify predictive factors for
a favorable therapeutic response.
Methods
Study design
This retrospective cohort study is based on data of the registry
of the German Neuromyelitis Optica Study Group (NEMOS,
nemos-net.de). Final data entry varied across centers and was
performed between January 2012 and March 2013. At this
time, the registry contained 215 patients with both NMO
diagnosed according to the 2006 Wingerchuk criteria11 and
AQP4-ab-seropositive NMOSD.12
Previously, we identified and characterized 1,124 attacks in
186 patients with NMO and NMOSD, treated at 6 regional
hospitals and 16 tertiary referral centres.3 Of these, all attacks
treated with an apheresis therapy, PE or IA, were included in
this subgroup analysis. Twelve centers used both PE and IA, 9
centers used only PE, and 1 center used only IA. Further
details on data collection, quality, and processing can be found
in the original characterization of the cohort.3
For each patient, demographic and diagnostic data, as well as
the number and dates of acute attacks from disease onset to
last follow-up, were included in the analysis. Moreover, attack-
related clinical features (Expanded Disability Status Scale
[EDSS] and visual acuity were available) and information on
attack treatment and outcome were assessed from the patient
records. The definition of an attack followed the definition
used for MS relapses: an objective neurologic worsening
lasting for at least 24 hours in the absence of fever or infec-
tions and occurring more than 30 days after the previous
attack. All attacks were confirmed by neurologic examination.
PE and IA were conducted according to local standard pro-
cedures. IA was performed using tryptophan (TR-350;
Diamed Medizintechnik GmbH) or protein A (Immuno-
sorba; Fresenius Medical Care) as an adsorber. One apheresis
treatment course was defined as at least 3 therapeutic PEs or
at least 3 IAs.
Short-term remission status of attack-related neurologic def-
icits was chosen as the primary outcome parameter and rated
as complete remission (CR) when there was full recovery,
partial remission (PR) when there was incomplete recovery,
and no remission (NR) when there was no improvement at all
of the attack-related neurologic deficits in relation to the
therapy cycle. The remission status was evaluated immedi-
ately after the end of the apheresis therapy.
The primary research question was to evaluate whether PE or
IA was more beneficial for NMOSD attack therapy. Given its
retrospective nature, this study was expected to provide Class
IV evidence.
Standard protocol approvals, registrations,
and patient consents
Ethics approval was obtained from the Institutional Review
Board of the Ruhr University Bochum (#4573-13) and of the
participating centers. Patients provided written informed
Glossary
AQP4-ab = aquaporin-4; CR = complete remission; EDSS = Expanded Disability Status Scale; GEE = generalized estimating
equation; IA = immunoadsorption; IQR = interquartile range; NEMOS = Neuromyelitis Optica Study Group; NMOSD =
neuromyelitis optica spectrum disorder;NR = no remission;ON = optic neuritis; PE = plasma exchange; PR = partial remission.
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consent. The study was performed according to ICH/GCP
and current German legal requirements; it was not registered
because registration was neither required nor available for
retrospective, noninterventional studies at the time of data
collection.
Statistical analysis
Patient characteristics were descriptively analyzed. Com-
parison of the use as first-line or consecutive treatment of PE
and IA, as well as distribution among treatment courses and
clinical attack manifestation, was performed using the exact
χ2 test. Generalized estimating equations (GEEs)13 with
remission status (CR vs PR or NR) of attacks as the de-
pendent variable were used for the analysis of direct com-
parisons of the effectiveness of PE vs IA in the first- or
second-line use. ORs with 95% CIs and corresponding p
values were given. GEE analyses with the same dependent
variable were also used to identify predictors of outcome.
The following variables were analyzed: sex, age at attack,
time from onset of disease to attack, AQP4-status, NMO vs
NMOSD, clinical manifestation (absence or presence of
myelitis, isolated manifestation of optic neuritis [ON] or
myelitis vs simultaneous), disease-modifying immunother-
apy, time from onset of attack to initiation of therapy,
apheresis as first- vs second-line therapy, technique of
therapy (PE vs IA), and center (to control for a center ef-
fect). We indicated missing data in the figure legends; the
corresponding observations were dropped in the multivari-
ate statistical analyses as usual. p Values < 0.05 were con-
sidered statistically significant. All tests were performed as
exploratory data analysis, therefore, no adjustments for
multiple testing were made. IBM SPSS Statistics, Version 24,
STATA (Data Analysis and Statistical Software; StataCorp
LP) and StatXact 6 (CYTEL Software Corp) were used for
computations and GraphPad Prism version 6.0f (GraphPad
Software) for visualization.
Data availability
As far as permitted, according to data protection requirements
and consent provided by the participants, original data are
available from the corresponding author on request from any
qualified investigator within 5 years after publication.
Results
Demographic and clinical characteristics
Among the initial 1,124 attacks in 186 patients, 253 attacks
were excluded due to insufficient data, 42 were not treated,
and 622 attacks did not receive an apheresis therapy
(figure 1).
Two hundred and seven attacks in 105 patients were treated
with apheresis therapies, of these 189 with a single apheresis
therapy and 18 with multiple apheresis therapies. A total of
192 PE (in 99 patients) and 38 IA procedures (in 23 patients),
each with at least 3 exchanges, were examined. Patient and
attack characteristics are given in table 1.
Apheresis therapies were applied as first-line choice in 72
attacks, as second-line (another attack therapy was given be-
fore the start of apheresis therapy) in 98 attacks, and as third-
line or later (2 or more previous attack therapies were given)
in 37 attacks. Time from onset of attack to start of therapy was
Figure 1 Study flow chart
HD-S = high-dose IV steroids; IA = immunoadsorption; PE = plasma exchange.
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median 1 day (interquartile range [IQR] 0–4, n = 58) in first-
line therapy, 11.5 days (IQR 5.0–22.75, n = 92) in second-line
therapy, and 15.5 days (IQR 10–45.75, n = 32) in third-line or
later therapy. No difference between PE and IA usage was
found in terms of distribution among lines of therapy (p =
0.303, exact χ2 test) and clinical attack manifestation (p =
0.055, exact χ2 test, figure 2).
PE and IA are both effective in the therapy of
NMOSD attacks
Both PE and IA were effective and induced at least PR in most
attacks when used as first- to fifth-line therapy (figure 3, A and
B). Although attacks treated with IA always showed a clinical
response as nonresponders were not found in this treatment
group, we could not show a difference in efficacy between PE
and IA (p = 0.264, GEE analysis, CR as the dependent vari-
able) (figure 3C). There was also no difference for the change
in EDSS between PE and IA (figure 3D). Because of over-
lapping effects of preceding attack therapies, we excluded
third- to fifth-line apheresis therapies from this statistical
analysis. Clinical characteristics of first- and second-line
apheresis therapies are given in table 2.
The use of apheresis therapies as first-line and
early therapy is associated with the highest
remission rate
CR was only reached with apheresis therapy initiated early
(first- and second-line therapy in IA, first- to third-line therapy
in PE). Forty percent of patients had CR when apheresis
therapy was started without delay, i.e., day 0–2 after onset of
symptoms, but improvement declined stepwise with later
treatment start (figure 3E). No patient completely recovered
when apheresis therapy was commenced later than 20 days
after symptom onset. CR was reached more often with early
PE (start after symptom onset day 0–6: 29%; day ≥7: 3.7%, n =
144 attacks) than with early IA treatment (start after symptom
onset day 0–6: 6.7%; day ≥7: 0%, n = 28 attacks).
Table 1 Patient characteristics
Patients (n = 105)
NMOa (n, %) 84 (80%)
AQP4-ab positive NMOSDb (n, %) 21 (20%)
Female sex (n, %) 82 (78%)
Age at onset (y; mean, SD) 43.4 (14.7)
Disease onset to last visit (y; median, IQR) 5.9 (3.0–10.1)
AQP4-ab positivec (n, %) 91 (87%)
≥1 optic neuritis ever (n, %) 87 (83%)
≥1 myelitis ever (n, %) 102 (97%)
Relapsing disease coursed (n, %) 99 (94%)
Attacks/patient (n, IQR) 5 (3–8)
ARR (n = 97; median, IQR)e 0.91 (0.63–1.46)
Abbreviations: AQP4-ab = anti-aquaporin-4 antibody; ARR = annualized re-
lapse rate; IQR = interquartile range; NMO = neuromyelitis optica; NMOSD =
neuromyelitis optica spectrum disorder.
a According to 2006 Wingerchuk criteria.11
b According to Wingerchuk et al. 2007.12
c AQP4-ab result not available in 1 NMO patient.
d Two or more attacks.
e Only patients with follow-up >1 year.
Figure 2 Overview of apheresis therapies
Plasma exchange and immunoadsorption were applied at similar frequencies for escalation from first- to fifth-line treatment (A) and for various clinical
manifestations (B) of NMOSD attacks. The chi-square test was used for statistical analysis. IA = immunoadsorption; MY = myelitis; ON = optic neuritis; PE =
plasma exchange.
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For multivariate GEE analyses of predictors of CR, we fur-
ther excluded attacks that were treated with an apheresis
therapy in both first and second line of treatment (n = 3),
attacks where a second-line apheresis therapy was not pre-
ceded by high-dose steroids (n = 4), and attacks with missing
clinical information (n = 24). Therefore, multivariate
analyses were possible in 139 attacks in 79 patients (see flow
chart figure 1).
Strong predictors for CR were the use of apheresis therapy as
first-line therapy (OR 12.271; 95%CI: 1.04–144.91, p = 0.047),
time from onset of attack to start of therapy in days (OR 0.937;
Figure 3 Clinical outcome of apheresis therapies for NMOSD attacks
Remission status of all attacks (total n = 207) treatedwith plasma exchange (A) or immunoadsorption (B).Missing data plasmaexchange: 1st line, n = 1; 2nd line,
n = 4; 3rd line, n = 6; and 4th line, n = 1. (C) Short-term remission status after first- or second-line therapy with plasma exchange or immunoadsorption.
Treatment courses with PE/IA as first- and second-line therapy were excluded (n = 2). Missing data plasma exchange: 1st line, n = 1 and 2nd line, n = 4.
Generalized estimationequationswith complete remission as thedependent variablewereused for statistical analysis. (D) Change in EDSSafter first or second-
line therapywithplasmaexchange (gray triangles) or immunoadsorption (red triangles).Missing data plasmaexchange: 1st line, n = 19; 2nd line, n = 30;missing
data immunoadsorption: 1st line, n = 7 and 2nd line, n = 15. One out of range value (immunoadsorption, −6.0) is not shown. Generalized estimation equations
were used for statistical analysis. TheMedian is highlighted as black line. (E) Short-term remission status after apheresis therapy according to time intervals of
attack onset to start of therapy. CR = complete remission; IA = immunoadsorption; NR = no remission; PE = plasma exchange; PR = partial remission.
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95% CI: 0.89–0.99, p = 0.014), and the presence of AQP4-abs
(OR 33.338; 95% CI: 1.76–631.17, p = 0.019) (table 3).
Monofocal attack manifestations were more likely to show CR
than multifocal attacks (OR 4.709; 95% CI: 1.03–21.62, p =
0.046). Age (per year) was an intermediate predictor (OR
0.925; 95% CI: 0.85–1.01, p = 0.081): the chance to have a CR
of attack symptoms decreasedwith age by approximately 8% per
year. Other factors such as apheresis technique, sex, center,
diagnosis of NMO vsNMOSD, disease duration, or presence of
disease-modifying immunotherapy did not predict CR.
Discussion
Two hundred and seven NMOSD attacks in 105 patients
were identified in the NEMOS registry, which were all treated
with an apheresis therapy (PE or IA). Confirming previous
reports from smaller patient cohorts,14–22 both PE and IA
were effective in the therapy of NMOSD attacks. We could
not detect differences between the 2 apheresis techniques
with regard to clinical outcome. Although techniques are
different, both therapies aim at eliminating circulating anti-
bodies from the patient’s circulation. This is of particular
importance in patients with NMOSD. Accordingly, our
analysis revealed that the presence of serum AQP4-abs was
a strong predictor for CR after apheresis therapies. This is in
contrast to observations from other case series, where effec-
tiveness of apheresis therapy was independent of the AQP4-
ab serostatus16,17,23 and supports the notion that AQP4-abs
have direct pathogenic effects. Nevertheless, these differences
have to be interpreted with caution as endpoints in these case
series were different. Moreover, the analyzed number of se-
ropositive patients in our GEE analysis was more than 10
Table 2 First- and second-line use of apheresis therapies for NMOSD attacks
First line (n = 72) Second line (n = 101)
PE (n = 63) IA (n = 9)
p
Value PE (n = 83) IA (n = 18)
p
Value
Characteristics of attacks and
therapies
Isolated optic neuritis (n, %) 10 (15.9%) 2 (22.2%) 0.879a 14 (16.9%) 6 (33.3%) 0.167a
Isolated myelitis (n, %) 44 (69.8%) 6 (66.7%) 55 (66.3%) 12 (66.7%)
MY + ON (n, %) 9 (14.3%) 1 (11.1%) 13 (15.7%) 0
Age at attack (y; mean, SD) 44.9 (16.3) 38.2 (7.7) 0.192b 49.6 (14.4) 39.0 (9.4) 0.002b
Disease duration (y; median, IQR) 3.3 (0.8–9.0) 4.6 (2.8–8.8) 0.216b 2.7 (0.2–6.1) 2.5 (0.8–4.8) 0.845b
Attack number (median, IQR) 6 (3–12) 4 (3–8) 0.411b 4 (2–7) 4 (3–7) 0.524b
EDSS at start of therapy (median,
IQR)
6.0 (3.5–7.5) (n = 50) 8.5 (4.5–9.5) (n = 3) 0.116b 7.0 (4.1–8.0) (n = 56) 5.8 (3.9–7.1) (n = 6) 0.281b
HD-S as first-line therapy (n, %) NA NA NA 77 (92.8%) 17 (94.4%) 0.800a
Time from attack onset to start of
therapy (d; median, IQR)
1 (0–4) (n = 52) 1.5 (0–18) (n = 6) 0.548b 13 (6–23) (n = 74) 6 (5–24) (n = 18) 0.321b
No. of exchanges (median, IQR) 5 (5–8) (n = 55) 8 (5.75–9) (n = 6) 0.020b 5 (5–7) (n = 75) 5 (5–6) (n = 17) 0.552b
Plasma exchange volume per
session (l; median, IQR)
3 (2.5–3.5) (n = 15) 2 (n = 1) NA 2.5 (2.35–3.5) (n = 28) 2 (1.5–2.55) (n = 9) 0.063b
Characteristics of patients
Treated patients (n) 28 7 70 15
NMO (n, %) 22 (78.6%) 6 (85.7%) 0.673a 55 (78.6%) 12 (80%) 0.902a
AQP4-ab positive NMOSD (n, %) 6 (21.4%) 1 (14.3%) 15 (21.4%) 3 (20%)
Female sex (n, %) 23 (82.1%) 6 (85.7%) 0.823a 54 (77.1%) 13 (86.7%) 0.413a
AQP4-ab positive (n, %) 26 (92.9%) 5 (71.4%) 0.111a 60 (87%) 15 (100%) 0.139a
Abbreviations: AQP4-ab = anti-aquaporin-4 antibody; EDSS = Expanded Disability Status Scale; HD-S = high-dose IV steroids; IA = immunoadsorption; IQR =
interquartile range; MY = myelitis; NA = not applicable; NMO = neuromyelitis optica; NMOSD = neuromyelitis optica spectrum disorder; ON = optic neuritis;
PE = plasma exchange.
Characteristics of attacks and therapies andbelow characteristics of treated patients (total, n = 90).Missing data second line:MY+ON (n = 1), AQP4-ab status (n = 1).
Significant values (p < 0.05) are shown in bold.
a χ2 test.
b Mann-Whitney test was used for statistical analysis.
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times as high as the seronegatives, resulting in considerable
statistical uncertainty. Therefore, apheresis therapies should
also be considered in antibody-negative NMOSD patients.
In NMOSD attacks, escalation and sequence of therapy is
decisive, and we have previously observed an advantage for
patients treated with apheresis therapies as a first choice when
the spinal cord was affected.3 Here, we could not show a su-
periority for one of the 2 different apheresis techniques in the
use as first-line therapy. Because of the small numbers of
patients with IA therapy included in our study, our data could
be biased. A definite comparison between the 2 techniques
should be conducted in a prospective randomized clinical trial
with appropriate patient numbers. In the absence of further
evidence, the decision to use one of both techniques should be
made taking availability, side effects, economic factors, and
patient preferences into account.24
The time between attack onset and start of therapy is decisive,
and early initiation of PE was shown to be a predictor of good
outcome in studies of CNS demyelination.25,26 In a recent
study, early initiation of PE within 5 days was identified as
a strong predictor for CR of severe attacks in patients with
NMOSD.27 Most of our patients received apheresis after
a remarkably short period, usually because they had experi-
enced insufficient remission of earlier relapses on steroid
treatment and were being treated at tertiary care centers with
immediate availability of apheresis therapies. Indeed, time
from onset of attack to start of therapy was also a strong
predictor in our current study, and an immediate start (within
2 days of symptom onset) was associated with a 40% rate of
CR as compared to 3.2% when started later as 6 days after
symptom onset. Whether high-dose steroids should be given
shortly before or concomitant with apheresis therapy is,
however, an open question. In our previous study, first-line
exclusive apheresis therapy without high-dose steroid pulse
therapy was superior to first-line high-dose steroids in cases of
isolated myelitis, but not in ON.3 The concomitant applica-
tion of high-dose steroids started on the day of admission, and
PE initiated “as early as possible” is a procedure reported to be
highly efficient in patients with severe NMOSD attacks.16,27
Monofocal vs multifocal attack manifestation was also a pre-
dictor of CR with apheresis therapies. However, it has to be
noted that monofocal attacks principally have a better chance
to recover completely compared with multiregional in-
volvement independent of the chosen attack therapy.3
Because of its retrospective nature, our study has limitations.
Nevertheless, the analysis comprises one of the largest data
sets assembled so far for the analysis of apheresis therapies in
NMOSD attacks. Data quality was highly ensured by the
“flying doctor” approach as previously described; briefly, 2
neurologists visited the contributing centers and used a pre-
defined standardized evaluation form to assess clinical data.3
However, bias cannot be excluded. Particularly the decision
on therapy modality, IA or PE, and on the time point when
apheresis therapy was started was an individual decision of the
treating physician. A center effect could be excluded in our
data set, reflecting a high standard and good availability of
apheresis therapies in the participating centers. Unfortunately,
data of attack severity or tolerability of therapy were not
systematically registered and could therefore not be included
in our analysis. In addition, delayed improvement may have
been missed because remission status was assessed at the
conclusion of apheresis, and no prespecified follow-up visits
were performed; because this applied to both PE and IA
groups, however, it is unlikely to have compromised our main
finding. Of interest, concomitant long-term immunotherapy
had influence neither on the use of apheresis therapy nor on
its effectiveness.
This study has immediate implications for clinical manage-
ment of NMOSD attacks. The early start of apheresis thera-
pies is strongly recommended. Whether IA or PE is used can
be decided individually.
Author contributions
I. Kleiter and C. Trebst designed the study, analyzed the data,
created the figures, conducted literature research, and wrote
the manuscript. K-D. Wernecke performed statistical analysis.
Table 3 Factors associatedwith complete remission from
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Appendix 1 Coinvestigators of the Neuromyelitis Optica Study Group (NEMOS) in alphabetical order. All institutions are
in Germany, unless otherwise indicated
Name Affiliation Role Contribution
Albrecht, P. University of Du¨sseldorf Site investigator Collected data
Ayzenberg, I. Ruhr-University Bochum Site investigator Collected data
Bayas, A. Klinikum Augsburg Site investigator Collected data
Bellmann-Strobl, J. Charite´ University Medicine Berlin Site investigator Collected data
Bischof, F. University of Tu¨bingen Site investigator Collected data
Bittner, S. Johannes Gutenberg University Mainz Site investigator Collected data
Continued
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Appendix 1 Coinvestigators of the Neuromyelitis Optica Study Group (NEMOS) in alphabetical order. All institutions are
in Germany, unless otherwise indicated (continued)
Name Affiliation Role Contribution
Bo¨ttcher, T. Bonhoeffer Klinikum Neubrandenburg Site investigator Collected data
Brettschneider, J. University of Ulm Site investigator Collected data
Buttmann, M. Caritas Hospital Bad Mergentheim Site investigator Collected data
DSouza, M. Charite´ University Medicine Berlin Site investigator Collected data
Ettrich, B. University of Leipzig Site investigator Collected data
Frank, B. University of Essen Site investigator Collected data
Gass, A. University hospital Mannheim Site investigator Collected data
Grothe, M. University of Greifswald Site investigator Collected data
Guthke. K. Klinikum Go¨rlitz Site investigator Collected data
Haarmann, A. University of Wu¨rzburg Site investigator Collected data
Habedank, E. University of Go¨ttingen Site investigator Collected data
Hoffmann, F. Krankenhaus Martha-Maria Halle Site investigator Collected data
Hoffmann, O. St. Josefs-Krankenhaus Potsdam Site investigator Collected data
Hu¨mmert, M.W. Hannover Medical School Site investigator Collected data
Junghans, J. Krankenhaus Martha-Maria Halle Site investigator Collected data
Kaste, M. Nordwest-Krankenhaus Sanderbusch Site investigator Collected data
Kaulen, B. University of Hamburg Site investigator Collected data
Kermer, P. Nordwest-Krankenhaus Sanderbusch Site investigator Collected data
Kern, P. Asklepios Klinik Teupitz Site investigator Collected data
Klotz, L. University of Mu¨nster Site investigator Collected data
Ko¨hler, W. Universita¨tsklinikum Leipzig Site investigator Collected data
Kolesilova, E. Asklepios Klinik Teupitz Site investigator Collected data
Korsen, M. University of Mu¨nster Site investigator Collected data
Kowarik, M. University of Tu¨bingen Site investigator Collected data
Langel, S. Landeskrankenhaus Rheinhessen Site investigator Collected data
Lee, D.H. University of Erlangen Site investigator Collected data
Liebetrau, M. St. Josefs-Hospital Wiesbaden GmbH Site investigator Collected data
Luessi, F. Johannes Gutenberg University Mainz Site investigator Collected data
Marouf, W. University Hospital Bonn Site investigator Collected data
Meister, S. University of Rostock Site investigator Collected data
Melms, A. University of Erlangen Site investigator Collected data
Metz, I. University of Go¨ttingen Site investigator Collected data
Mu¨nch, C. Charite´ University Medicine Berlin Site investigator Collected data
Niehaus, S. Klinikum Dortmund Site investigator Collected data
Pawlitzki, M. University of Magdeburg Site investigator Collected data
Pellkofer, H. Ludwig-Maximilians University Munich Site investigator Collected data
Puhlmann, H.U. Schlosspark-Klinik Berlin Site investigator Collected data
Continued
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